462 results on '"Asadullah K"'
Search Results
2. Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study
3. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study
4. 587 Higher IL-10+ T cell and treg cell counts in psoriatic skin are associated with super-response to guselkumab: Data from the phase 3 guide trial
5. Acute and Chronic Models of Allergic Contact Dermatitis: Advantages and Limitations
6. 083 Prolonged Q16W treatment interval of guselkumab is non-inferior to Q8W dosing for maintaining disease control in super responders: primary results from GUIDE at Week 68 in patients with psoriasis
7. Topical Glucocorticoid Therapy in Dermatology
8. SEGRAs: A Novel Class of Anti-inflammatory Compounds
9. Facteurs pronostiques potentiels d’une réponse PASI 100 précoce chez les patients traités par guselkumab : résultats de l’étude GUIDE
10. LB943 Prediction of super response and drug-free disease control in guselkumab patients using multivariate baseline serum biomarkers: data from part 3 of GUIDE trial
11. Zirkulierende maligne und benigne Lymphozyten in Frühstadien kutaner Lymphome
12. Interleukin-10 als immunsuppressives Zytokin: Bedeutung für die Dermatologie
13. Interleukin-10 receptor-1 expression in monocyte-derived antigen-presenting cell populations: dendritic cells partially escape from IL-10's inhibitory mechanisms
14. Real‐world evidence from the non‐interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab
15. Improvement of Monocyte Function — A New Therapeutic Approach?
16. Enhancing potato crop yield with AI-powered CNN-based leaf disease detection and tracking
17. Étude GUIDE (partie 3) : impact de la durée d’évolution du psoriasis sur la rémission à long terme après arrêt du guselkumab
18. Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines
19. Is there an interaction between interleukin-10 and interleukin-22?
20. Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart
21. Einsatz von Biologicals bei Psoriasis in der Dermatologie
22. A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta
23. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes
24. IL-24 expression during early wound healing phase is depended on an inflammatory environment: P218
25. Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use
26. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases
27. Influence of monomethylfumarate on monocytic cytokine formation – explanation for adverse and therapeutic effects in psoriasis?
28. Different release of cytokines into the cerebrospinal fluid following surgery for intra- and extra-axial brain tumours
29. Long-term interleukin-10 presence induces the development of a novel, monocyte-derived cell type
30. IL-7 mRNA is not overexpressed in mycosis fungoides and pleomorphic T-cell lymphoma and is unlikely to be an autocrine growth factor in vivo
31. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis
32. Étude GUIDE (partie 3) : les patients super-répondeurs qui ont arrêté le guselkumab pendant une longue période ont rapidement retrouvé un contrôle de la maladie à la reprise du traitement
33. Analyzing Factors Attributing To Effectiveness of Performance Management System of a Manufacturing Industry
34. Gene expression profile in the skin of patients with allergic contact dermatitis
35. IL-22 increases the innate immunity of the skin: 724
36. Induction of heme oxygenase-1 (HO-1) inhibits T cell-dependent skin inflammation and depresses dendritic cell maturation and function in vitro: 722
37. Potent immunomodulatory effects on immune cells mediated by a dissociated vitamin D3 Analog: 663
38. Efomycine M: a pan-selectin antagonist?: 092
39. Molecular mechanisms of interleukin-10-mediated inhibition of NF-κB activity: a role for p50
40. Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis
41. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype
42. Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis
43. Cytokines: interleukin and interferon therapy in dermatology
44. Cytokine therapy in dermatology
45. NRAMP gene family in Kandelia obovata: genome-wide identification, expression analysis, and response to five different copper stress conditions
46. Erratum: Interleukin-10 receptor-1 expression in monocyte-derived antigen-presenting cell populations: dendritic cells partially escape from IL-10's inhibitory mechanisms
47. Dealing with the issue 'care of the dying' in medical education - results of a survey of 592 European physicians
48. CMV-activation in psoriasis - association with systemic TNF-α overexpression
49. Clinical and immunological effects of IL-10 therapy in psoriasis
50. A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor α overexpression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.